Recent Advances in the Drugs and Glucose-Responsive Drug Delivery Systems for the Treatment of Diabetes: A Systematic Review.

IF 4.9 3区医学 Q1 PHARMACOLOGY & PHARMACY Pharmaceutics Pub Date : 2024-10-20 DOI:10.3390/pharmaceutics16101343

Junyu Liu, Xudong Yi, Jinrui Zhang, Yiman Yao, Pharkphoom Panichayupakaranant, Haixia Chen

{"title":"Recent Advances in the Drugs and Glucose-Responsive Drug Delivery Systems for the Treatment of Diabetes: A Systematic Review.","authors":"Junyu Liu, Xudong Yi, Jinrui Zhang, Yiman Yao, Pharkphoom Panichayupakaranant, Haixia Chen","doi":"10.3390/pharmaceutics16101343","DOIUrl":null,"url":null,"abstract":"<p><p>Diabetes is a common chronic metabolic disease. Different types of drugs play important roles in controlling diabetes and its complications, but there are some limitations. The glucose-responsive drug delivery system is a novel technology with potential in diabetes treatment. It could automatically release drugs in response to changes in glucose levels in the body to maintain blood glucose within a normal range. The emergence of a glucose-sensitive drug delivery system provides a more intelligent and precise way to treat diabetes. The review is carried out according to the Preferred Reporting Items for Systematic Reviews (PRISMA 2020) guidelines This review focuses on the recent advances in the drugs and different systems of glucose-sensitive drug delivery, including glucose oxidase, phenylboronic acid, Concanavalin A, and other glucose-reactive systems. Furthermore, the glucose-responsive drug delivery system combined with the application applied in hydrogels, microneedles, and nanoparticles is also explored and summarized. The new platforms to sustain the release of anti-diabetic drugs could be desirable for patients. It could lead to increased adherence and glycemic outcomes for the detection and treatment of diabetes. Furthermore, given the limitations of glucose-responsive drug delivery systems, solutions and perspectives are proposed to help the understanding and application of these systems. This review will be helpful for drug discovery and treatment of diabetes from a new perspective.</p>","PeriodicalId":19894,"journal":{"name":"Pharmaceutics","volume":"16 10","pages":""},"PeriodicalIF":4.9000,"publicationDate":"2024-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11511183/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmaceutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/pharmaceutics16101343","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Diabetes is a common chronic metabolic disease. Different types of drugs play important roles in controlling diabetes and its complications, but there are some limitations. The glucose-responsive drug delivery system is a novel technology with potential in diabetes treatment. It could automatically release drugs in response to changes in glucose levels in the body to maintain blood glucose within a normal range. The emergence of a glucose-sensitive drug delivery system provides a more intelligent and precise way to treat diabetes. The review is carried out according to the Preferred Reporting Items for Systematic Reviews (PRISMA 2020) guidelines This review focuses on the recent advances in the drugs and different systems of glucose-sensitive drug delivery, including glucose oxidase, phenylboronic acid, Concanavalin A, and other glucose-reactive systems. Furthermore, the glucose-responsive drug delivery system combined with the application applied in hydrogels, microneedles, and nanoparticles is also explored and summarized. The new platforms to sustain the release of anti-diabetic drugs could be desirable for patients. It could lead to increased adherence and glycemic outcomes for the detection and treatment of diabetes. Furthermore, given the limitations of glucose-responsive drug delivery systems, solutions and perspectives are proposed to help the understanding and application of these systems. This review will be helpful for drug discovery and treatment of diabetes from a new perspective.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

治疗糖尿病的药物和葡萄糖反应性给药系统的最新进展：系统综述》。

糖尿病是一种常见的慢性代谢性疾病。不同类型的药物在控制糖尿病及其并发症方面发挥着重要作用，但也存在一些局限性。葡萄糖反应给药系统是一种新型技术，具有治疗糖尿病的潜力。它可以根据体内葡萄糖水平的变化自动释放药物，将血糖维持在正常范围内。葡萄糖敏感给药系统的出现为治疗糖尿病提供了一种更智能、更精确的方法。本综述根据系统性综述首选报告项目（PRISMA 2020）指南进行撰写，重点介绍了葡萄糖氧化酶、苯硼酸、Concanavalin A 和其他葡萄糖反应系统等葡萄糖敏感给药药物和不同系统的最新进展。此外，还探讨和总结了葡萄糖反应给药系统与水凝胶、微针和纳米颗粒中的应用相结合的情况。对于患者来说，持续释放抗糖尿病药物的新平台是可取的。它可以提高检测和治疗糖尿病的依从性和血糖结果。此外，鉴于葡萄糖反应给药系统的局限性，本文还提出了有助于理解和应用这些系统的解决方案和观点。这篇综述将有助于从新的视角发现和治疗糖尿病的药物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Pharmaceutics Pharmacology, Toxicology and Pharmaceutics-Pharmaceutical Science

CiteScore

7.90

自引率

11.10%

发文量

2379

审稿时长

16.41 days

期刊介绍： Pharmaceutics (ISSN 1999-4923) is an open access journal which provides an advanced forum for the science and technology of pharmaceutics and biopharmaceutics. It publishes reviews, regular research papers, communications, and short notes. Covered topics include pharmacokinetics, toxicokinetics, pharmacodynamics, pharmacogenetics and pharmacogenomics, and pharmaceutical formulation. Our aim is to encourage scientists to publish their experimental and theoretical details in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced.